Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

3.4%

7 terminated/withdrawn out of 204 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

19%

39 trials in Phase 3/4

Results Transparency

4%

1 of 25 completed trials have results

Key Signals

46 recruiting1 with results6 terminated

Enrollment Performance

Analytics

Phase 2
69(51.1%)
N/A
25(18.5%)
Phase 4
21(15.6%)
Phase 3
18(13.3%)
Phase 1
2(1.5%)
135Total
Phase 2(69)
N/A(25)
Phase 4(21)
Phase 3(18)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (204)

Showing 20 of 204 trials
NCT04937283Not ApplicableRecruiting

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Role: lead

NCT07517640Phase 2Not Yet Recruiting

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Role: lead

NCT07134660Not ApplicableRecruiting

Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine

Role: lead

NCT07494591Not ApplicableNot Yet Recruiting

TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery

Role: lead

NCT07493980Phase 2Not Yet Recruiting

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Role: lead

NCT07309393Not ApplicableRecruiting

Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function

Role: lead

NCT07469488Phase 4Not Yet Recruiting

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Role: lead

NCT07434518Recruiting

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

Role: collaborator

NCT07408635Phase 2Recruiting

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Role: lead

NCT07410975Phase 2Recruiting

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Role: lead

NCT07393438Phase 2Not Yet Recruiting

Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

Role: lead

NCT07393386Phase 4Not Yet Recruiting

Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial

Role: lead

NCT07375979Not Yet Recruiting

A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

Role: lead

NCT06427018Recruiting

Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients

Role: collaborator

NCT07328945Recruiting

Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer

Role: lead

NCT06298058Phase 1Recruiting

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Role: collaborator

NCT07323056Phase 2Recruiting

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Role: lead

NCT07295938Phase 2Recruiting

TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease

Role: collaborator

NCT06293690Phase 2Active Not Recruiting

Toripalimab Combined With SBRT for NSCLC

Role: lead

NCT07274761Phase 2Active Not Recruiting

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Role: lead